United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 5,060 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $237.52, for a total transaction of $1,201,851.20. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $30,877.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
United Therapeutics Trading Up 0.0 %
United Therapeutics stock traded up $0.08 during mid-day trading on Tuesday, hitting $237.04. 399,157 shares of the stock were exchanged, compared to its average volume of 430,041. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $261.54. The firm's fifty day simple moving average is $228.15 and its two-hundred day simple moving average is $228.08. The stock has a market capitalization of $11.16 billion, a price-to-earnings ratio of 11.95 and a beta of 0.52.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The firm had revenue of $614.70 million during the quarter, compared to analyst estimates of $575.01 million. During the same quarter last year, the business earned $2.67 EPS. The company's revenue was up 25.1% compared to the same quarter last year. Analysts forecast that United Therapeutics Co. will post 23.46 EPS for the current year.
Institutional Trading of United Therapeutics
Several large investors have recently modified their holdings of UTHR. Great West Life Assurance Co. Can grew its position in shares of United Therapeutics by 8.9% during the 1st quarter. Great West Life Assurance Co. Can now owns 28,326 shares of the biotechnology company's stock worth $5,244,000 after buying an additional 2,320 shares during the period. Canada Pension Plan Investment Board grew its position in shares of United Therapeutics by 229.6% during the 1st quarter. Canada Pension Plan Investment Board now owns 2,063 shares of the biotechnology company's stock worth $371,000 after buying an additional 1,437 shares during the period. Prudential PLC acquired a new stake in shares of United Therapeutics during the 1st quarter worth approximately $1,160,000. Zions Bancorporation N.A. acquired a new stake in shares of United Therapeutics during the 1st quarter worth approximately $66,000. Finally, Covestor Ltd grew its position in shares of United Therapeutics by 187.5% during the 1st quarter. Covestor Ltd now owns 877 shares of the biotechnology company's stock worth $157,000 after buying an additional 572 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on the stock. Wells Fargo & Company upped their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a research note on Thursday, March 7th. Leerink Partnrs reiterated an "outperform" rating on shares of United Therapeutics in a research note on Monday, February 5th. SVB Leerink started coverage on shares of United Therapeutics in a research note on Monday, February 5th. They issued an "outperform" rating and a $330.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $300.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, The Goldman Sachs Group upgraded shares of United Therapeutics from a "sell" rating to a "neutral" rating and raised their price target for the company from $213.00 to $215.00 in a research note on Monday, February 12th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $294.40.
Get Our Latest Stock Analysis on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
